How do you manage patients with oligometastatic renal cell carcinoma after nephrectomy and metastatectomy?

Do you observe, offer adjuvant pembrolizumab, or give a first-line metastatic regimen (IO/IO or IO/TKI)? Does your recommendation vary based on risk classification?

1 Answer

Mednet MemberInvited Expert

Medical Oncology · Johns Hopkins Medicine

Answered on

Patients with oligometastatic renal cell carcinoma after nephrectomy and metastatectomy or M1 NED represent a challenging subset of patients given the heterogeneous nature of this subset and outcomes vary with the location and timing of metastatectomy.

Prior VEGF-TKI studies after metastasectomy for ...

Join for free or sign in to see the full answer